A co-payment suggests sharing the total cost between patients and payers. However, drug co-payments sometimes exceed costs, with the insurer or pharmacy benefit manager (PBM) keeping the difference.
1 Furthermore, some pharmacists are contractually prevented from alerting patients when their co-payment exceeds the drug's cash price. 2 Although some have argued that the practice is uncommon, a 2016 survey of independent pharmacists indicates otherwise. 3 Such overpayments have been the subject of lawsuits and state legislation, but little is known about their frequency or magnitude.
Methods | Pharmacies collect patients' co-payments and pass them to PBMs, who reimburse the pharmacy a negotiated rate to cover drug costs, dispensing fees, and any markup. Overpayments occur when the co-payment exceeds the negotiated reimbursement. To assess the frequency of overpayments, we compared co-payments with the national average reimbursement received by pharmacies for commercially insured patients for the same prescription.
The reimbursement data came from a survey by the Centers for Medicare & Medicaid Services from January to June 2013, the national average retail price (NARP). NARP data are based on 50 million retail pharmacy transactions from independent and chain pharmacies nationwide. They measure perunit mean reimbursement to retail pharmacies for commercially insured patients for more than 4000 common outpatient drugs and represent the total cost to the PBM, including dispensing fees and pharmacy markup. 4 We compared NARP reimbursements to co-payments from pharmacy claims from a 25% random sample of Optum's Clinformatics Data Mart from the same period. These claims come from 1.6 million commercially insured beneficiaries from 50 states, with greater representation from the south and less from the northeast compared with the US privately insured population. The data are representative in terms of sex, but overrepresent the age category of 21 to 64 years.
We identified claims in which co-payment exceeded NARP reimbursement, and the excess amount (overpayment).
To ensure the excess did not simply reflect variation in reimbursements (NARP measures average reimbursement), we conservatively identified overpayments only on claims in which the co-payment exceeded the NARP by more than $2.00 for reimbursements below $20 or 10% of the NARP for reimbursements above $20. We calculated the frequency and mean size of overpayments for all claims and performed 2-sided tests of equality between these values for brand drugs vs generic drugs (α = .05). We report results for all prescriptions together, and for the 20 drugs most frequently prescribed. Confidence intervals were binomial; all analyses were performed with Stata (StataCorp), version 14.0. The most commonly prescribed drug, hydrocodone/ acetaminophen, involved an overpayment on 36.15% of claims (95% CI, 35.99%-36.31%), with mean overpayment of $6.94 (SD, $4.27) ( Table 2) . Twelve of the 20 most commonly prescribed drugs involved overpayment rates above 33%.
Discussion | Overpayments were common in this data set, affecting 23% of all prescriptions, and 28% of generic prescriptions. Although the mean overpayment was relatively small, their widespread use on popular drugs resulted in a total cost of $10.51 per member. By comparison, 1 large PBM reported its clients spent $10.67 per member on metformin in 2016.
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Primary limitations were the use of pharmacy claims from a single, large insurer and national mean prices, which were only available for 2013 and may not represent current practice. Cost-related nonadherence is common and associated with increased medical services use and negative health outcomes. 6 By raising patient costs at the point of sale, overpayments may exacerbate these effects. To lower patient expenses, legislation addressing overpayments and gag clauses warrants further investigation.
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ICU Admission and Mortality Among Elderly Adults
To the Editor Dr Guidet and colleagues 1 investigated whether, among critically ill patients aged at least 75 years, systematic admission to an intensive care unit (ICU) vs usual practice reduced mortality at 6 months. In the trial, patients with cancer were excluded without explanation. In the United States, 47% of patients with cancer (active or in remission) are aged 70 years or older.
2 Only 3 studies have investigated the prognoses of elderly critically ill patients with cancer. The first study concerned patients with stage III or IV non-small cell lung cancers (aged ≥66 years) and reported poor results. More recently, Auclin et al 5 reported that patients 65 years or older with solid cancer admitted to a medical ICU of a teaching hospital accounted for 14.3% of ICU admissions during the study period. These patients had the same ICU mortality rate as patients without cancer. In addition, 52.7% of patients with cancer discharged from the ICU received anticancer treatment when indicated. We believe that there was no valid scientific argument to exclude older patients with cancer from the study by Guidet and colleagues.
1 The rapidly reversible character of organ failure and the functional status before admission to the emergency department (usually measured with the Eastern Cooperative Oncology Group performance status score, an essential marker for short-term and medium-term survival in this population) are most important. Elderly patients increasingly benefit from targeted therapies or immunotherapies and present to the emergency department for reasons other than cancer, with good functional status.
5 The decision to admit older patients with cancer to the ICU should be made by taking into account not only the clinical condition and the opinions of the emergency physician and the intensivist but also of the oncologist or the hematologist, requiring a broader discussion than described in the trial.
The benefit of ICU admission for elderly patients is controversial. In a previous observational cohort study including all critically ill patients 80 years or older presenting to the emergency department regardless of their underlying condition, an improvement in 6-month outcome in patients admitted to the ICU was not demonstrated. 3 In that study, 9.8% of included patients had an active cancer and they were similarly referred by an emergency physician for ICU admission. Overall, 12.4% of patients were admitted to the ICU, whereas 9.6% of patients with cancer were admitted. Active cancer was independently associated with 6-month mortality (odds ratio, 2.59 [95% CI, 1.74-3.90]).
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In a context in which intensive care may be refused to patients based only on their biological age, the ICE-CUB 2 study aimed to evaluate the benefit of ICU care for selected patients, those who should benefit the most from admission. We excluded patients with at least 1 of the 3 prognostic factors associated with poor 6-month survival identified in the ICE-CUB 1 study: active cancer, poor functional status, and poor nutritional status. The main end point was 6-month mortality, which is heavily influenced by comorbidities and functional status regardless of final hospital admission location (ICU or other wards).
Our trial does not imply that ICU admission is always futile for elderly patients. The subgroup of elderly patients with solid tumors deserves a specific assessment to identify favorable prognostic factors of long-term mortality, quality of life, and functional status. From that perspective, acute
